Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Immunic ( (IMUX) ).
On September 25, 2025, Immunic, Inc. announced the presentation of key data from their Phase 2 CALLIPER trial of vidofludimus calcium at the 41st Congress of ECTRIMS in Barcelona. The data demonstrated statistically significant improvements in disability for patients with progressive multiple sclerosis, highlighting the drug’s neuroprotective potential and supporting its advancement into Phase 3 trials. Additionally, long-term data from the Phase 2 EMPhASIS trial in relapsing-remitting multiple sclerosis showed high rates of patients remaining free of disability worsening and favorable safety profiles, underscoring vidofludimus calcium’s promise as a differentiated oral therapy in the MS market.
The most recent analyst rating on (IMUX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Immunic stock, see the IMUX Stock Forecast page.
Spark’s Take on IMUX Stock
According to Spark, TipRanks’ AI Analyst, IMUX is a Underperform.
Immunic’s overall stock score is primarily impacted by its challenging financial performance, marked by high R&D costs without corresponding revenue. Technical analysis shows moderate short-term bullish signals, but long-term valuation remains unattractive due to negative earnings and lack of dividends. The company’s ability to improve its financial position relies heavily on successful product commercialization or securing additional funding.
To see Spark’s full report on IMUX stock, click here.
More about Immunic
Immunic, Inc. is a biotechnology company focused on developing orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company’s lead asset, vidofludimus calcium, is being developed as a potential treatment for multiple sclerosis.
Average Trading Volume: 1,180,176
Technical Sentiment Signal: Sell
Current Market Cap: $86.72M
For an in-depth examination of IMUX stock, go to TipRanks’ Overview page.